Peptide Enforcement Discretion Policy
Salt Lake City – The US Department of Health and Human Services (HHS) has released an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with notice published in the Federal Register on October 30, 2026.
The Utah Division of Professional Licensing (DOPL) will exercise similar limited enforcement discretion in Utah, in strict accordance with the scope of this HHS interim policy.
DOPL will apply enforcement discretion only when each condition listed in the HHS interim policy is met.
Please Note:
- Authorized Facilities: Compounding and dispensing is strictly limited to state-licensed 503A compounding pharmacies.
- Patient-Specific Prescriptions: Every preparation must be compounded pursuant to a valid prescription for an individually identified patient.
- Prohibition on Office Use: Compounding for clinic stock or in-office use is strictly prohibited.
- Mandatory Reporting: Facilities must report all adverse events to both the FDA and DOPL.
For more information visit, see the Federal Register Notice.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
